Great minds are at work! Once enough Sermo physicians weigh in, the rating will be displayed here
KISUNLA contains the active ingredient donanemab-azbt, which is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody. It is prepared as an intravenous infusion solution at a concentration of 350 mg/20 mL and is available in single-dose vials. Key inactive ingredients include anhydrous citric acid, polysorbate 80, sodium citrate, and sucrose.
How should I use this medication?
This medication is infused into a vein. It is given by your care team in a hospital or clinic setting. A special MedGuide will be given to you before each treatment. Be sure to read this information carefully each time. Talk to your care team about the use of this medication in children. Special care may be needed.
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once. NOTE: This medicine is only for you. Do not share this medicine with others.
What if I miss a dose?
Keep appointments for follow-up doses. It is important not to miss your dose. Call your care team if you are unable to keep an appointment.
Where should I keep my medication?
This medication is given in a hospital or clinic. It will not be stored at home.
NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.
What side effects may I notice from receiving this medication?
Side effects that you should report to your care team as soon as possible: -Allergic reactions or angioedema—skin rash, itching or hives, swelling of the face, eyes, lips, tongue, arms, or legs, trouble swallowing or breathing -Headache, worsening confusion, dizziness, change in vision, nausea, seizures -Infusion reactions—chest pain, shortness of breath or trouble breathing, feeling faint or lightheaded Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome): -Headache
This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What should I tell my care team before I take this medication?
They need to know if you have any of these conditions: -Taking a blood thinner -An unusual or allergic reaction to donanemab, other medications, foods, dyes, or preservatives -Pregnant or trying to get pregnant -Breastfeeding
What may interact with this medication?
Interactions have not been studied.
This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.
What should I watch for while using this medication?
Visit your care team for regular checks on your progress. Tell your care team if your symptoms do not start to get better or if they get worse. This medication can cause a serious side effect called amyloid related imaging abnormalities (ARIA). ARIA can cause swelling or bleeding in the brain. Some people have a genetic risk factor that increases the risk of ARIA. Your care team may test you for this risk factor. The risk of bleeding in the brain is increased in people who take blood thinners. Talk to your care team if you take medications to prevent or treat blood clots. You will have imaging scans before and during your treatment to help your care team monitor for ARIA. Contact your care team right away if you have a severe headache, worsening confusion, dizziness, change in vision, nausea, trouble walking, or seizures.
What are the most serious risks of this medication?
This medication can cause a serious side effect called amyloid related imaging abnormalities (ARIA). ARIA can cause swelling or bleeding in the brain. Some people have a genetic risk factor that increases the risk of ARIA. Your care team may test you for this risk factor. Contact your care team right away if you have a severe headache, worsening confusion, dizziness, change in vision, nausea, trouble walking, or seizures.
Source: This information is sourced from Elsevier Inc.
The reviews, ratings, comments, and opinions expressed on this platform are solely those of the individual medical professionals who posted them and do not reflect the views or positions of Sermo, Inc. Sermo does not endorse, verify, or validate the content of individual reviews. The information provided is user-generated and reflects personal clinical experiences, which may not be complete, accurate, or applicable to your specific health needs. It is not intended as medical advice.
Prescription medications affect individuals differently, and what works for one person may not work for another. Always consult your doctor, pharmacist, or other qualified healthcare provider to ensure the information displayed applies to your personal circumstances. Only a licensed healthcare provider can advise you on what is safe and effective for you.
Keep all medications out of the reach of children, never share your medicine with others, and use each medication only as prescribed. Your reliance on any information provided on this platform is at your own risk.
Sermo Drug Ratings, and all information provided on this website, may not be used in combination with any artificial intelligence tool (including to train an algorithm, test, process, analyze, generate output and/or develop any form of artificial intelligence tool).
Visitors to the online patient-facing website at Sermo.com (“Sermo Drug Ratings”) are Authorized Users of the website, which contains data owned by a third-party provider, Elsevier, Inc. Accordingly, by visiting Sermo Drug Ratings, Authorized User acknowledges that the website includes Elsevier owned data that Sermo licenses pursuant to a separate usage and Data agreement (the “Agreements”). Authorized User further acknowledges that Sermo is a third-party beneficiary of the Agreements and Authorized User’s use of the website hereby binds them to the terms of the Agreements; provided, however, that Elsevier shall have no obligations or liability to an Authorized User whatsoever pursuant to the terms of the Agreements.
